

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT UNAUDITED OPERATING STATISTICS FOR THE YEAR ENDED DECEMBER 31, 2021

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the year ended December 31, 2021, and the comparative figures as set out below.

	For the period from January 1 to December 31		Change
	2021	2020	
	<i>RMB' million</i>	<i>RMB' million</i>	
	<i>(approximate)</i>	<i>(approximate)</i>	<i>%</i>
Revenue	178.0	27.6	545%
Gross Profit	131.6	16.3	698%
	<i>Approximate</i>	<i>Approximate</i>	
	<i>Percentage</i>	<i>Percentage</i>	
Gross Profit Margin	73%	59%	N/A

The increase of revenue was primarily attributable to: (i) the increased sales revenue of our key products approved in the second half of 2020, including Thrombite® Clot Retriever Device, Ultrafree® Drug Coated PTA Balloon Catheter and intracranial support catheter, which contributed approximately 70% of the total revenue for the year ended December 31, 2021; (ii) that in the year of 2021, we have obtained approvals from the National Medical Products Administration of the People's Republic of China (the “**NMPA**”) for 8 more products, which means a 100% success rate for NMPA registration approval as anticipated by the Company early in the year. Among those products, intracranial PTA balloon catheter (Rx) and PTA balloon catheter have contributed an important portion to the top line growth; and (iii) the effective establishment of our sales and marketing, and distribution network, which has helped us with the commercialization of our approved products.

The increase in gross profit margin was primarily attributable to: (i) the raw material price reduction due to the increased procurement volume; and (ii) more efficient production due to our continuously optimized production technology platform and increased production volume.

Notwithstanding the above, as disclosed in the prospectus of the Company dated June 22, 2021, the Group would continue to incur significant losses in 2021, as it continued to invest heavily in research and development activities to expand its development of and seek regulatory approvals for product candidates.

As the Company is still in the process of finalizing annual results of the Group for the year ended December 31, 2021, the information contained in this announcement is only based on the information currently available to the Board and the preliminary review by the Board on the unaudited management accounts of the Group for the year ended December 31, 2021, which have not been reviewed or audited by the independent auditors and/or the audit committee of the Company.

The actual financial results of the Group for the year ended December 31, 2021 may differ from what is disclosed in this announcement. Shareholders and potential investors are advised to read carefully the announcement of the Company in relation to the results of the Group for the year ended December 31, 2021, which is expected to be published in March 2022 in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The above operating information is provided for investors' reference only and it shall not be taken as a measure or indication of the Group's future financial performance.

SHAREHOLDERS AND POTENTIAL INVESTORS OF THE COMPANY ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, February 14, 2022

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.